Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Vancouver, Canada and Deerfield, Illinois, USA, February 19, 2007 -- Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) and its co-development partner Astellas Pharma US, Inc. today announced that the...
Read more about Cardiome and Astellas Announce Acceptance of NDA for Review
MELVILLE, N.Y.--(BUSINESS WIRE)--Jan. 29, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European...
Larger vial offers more convenient usage, less waste PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today the availability of their antifungal agent MYCAMINE® (micafungin sodium)...
Read more about Astellas Pharma US, Inc. Announces Availability of MYCAMINE® 100mg Vial
Submission of additional indication supports Astellas' commitment to the Infectious Disease community PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today that, on December 21,...
MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 15, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Committee...
Follow U.S. news
